The onset of CG following rituximab‐based therapy is due to a transient IgM increase, termed IgM flare, which may cause symptomatic hyperviscosity, exacerbate IgM‐related neuropathy, or aggravate CG and other complications. Here, CD40LG is linked to neuropathy.